We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Varian's (VAR) RapidPlan Gets Positive Feedback at AAPM
Read MoreHide Full Article
Oncology treatment therapy provider, Varian Medical Systems’ proprietary RapidPlan knowledge-based treatment planning software received good feedback at the 2016 American Association of Physicists in Medicine (AAPM).
Researchers Kathryn Masi and Maria Ditman from the University of Michigan, Ann Arbor, announced that per their research the RapidPlan software creates consistent, efficient and quality plans. Their conclusion also draws to the fact that the software simultaneously standardizes the treatment planning process. They used a prostate-specific RapidPlan model, based on 60 prostate intensity-modulated radiation therapy plans. They applied their knowledge-based planning model to 10 patients from four community-based clinics.
Per the researchers, the software can improve quality control in radiotherapy and radiosurgery treatment plans. The researchers are also of the opinion that using the RapidPlan tool helped them to develop plans that improved targeting of tumors and spared more healthy tissues.
RapidPlan is a machine-learning tool which studies the best practice from past successful treatment plans. The tool then creates knowledge-based treatment models that are applied to improve the treatment plans for future patients. These models help to quickly generate and validate new treatment plans based on earlier experience.
Going forward, Varian’s strong overseas presence is expected to help the company cash in on the opportunities in emerging markets. Notably, the company recorded healthy gross order growth in emerging markets like Iran, Russia, Ethiopia, Burkina Faso and Libya in the recently concluded third quarter of fiscal 2016. In Africa, Varian won gross orders worth $25 million.
We believe that Varian’s oncology business growth prospects are impressive in these countries due to strong demand for its products. The company is addressing both the tier-1 and mid-tier markets through its Edge, Truebeam and VitalBeam products. Moreover, the company believes that the Proton system has massive growth potential.
Headquartered in Palo Alto, CA, Varian is a leading provider of radiotherapy, radiosurgery, proton therapy and brachytherapy for the treatment of cancer and other medical conditions. It is also a premier supplier of X-Ray tubes for medical, scientific and industrial applications.
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Varian's (VAR) RapidPlan Gets Positive Feedback at AAPM
Oncology treatment therapy provider, Varian Medical Systems’ proprietary RapidPlan knowledge-based treatment planning software received good feedback at the 2016 American Association of Physicists in Medicine (AAPM).
Researchers Kathryn Masi and Maria Ditman from the University of Michigan, Ann Arbor, announced that per their research the RapidPlan software creates consistent, efficient and quality plans. Their conclusion also draws to the fact that the software simultaneously standardizes the treatment planning process. They used a prostate-specific RapidPlan model, based on 60 prostate intensity-modulated radiation therapy plans. They applied their knowledge-based planning model to 10 patients from four community-based clinics.
Per the researchers, the software can improve quality control in radiotherapy and radiosurgery treatment plans. The researchers are also of the opinion that using the RapidPlan tool helped them to develop plans that improved targeting of tumors and spared more healthy tissues.
RapidPlan is a machine-learning tool which studies the best practice from past successful treatment plans. The tool then creates knowledge-based treatment models that are applied to improve the treatment plans for future patients. These models help to quickly generate and validate new treatment plans based on earlier experience.
Going forward, Varian’s strong overseas presence is expected to help the company cash in on the opportunities in emerging markets. Notably, the company recorded healthy gross order growth in emerging markets like Iran, Russia, Ethiopia, Burkina Faso and Libya in the recently concluded third quarter of fiscal 2016. In Africa, Varian won gross orders worth $25 million.
VARIAN MEDICAL Price
VARIAN MEDICAL Price | VARIAN MEDICAL Quote
We believe that Varian’s oncology business growth prospects are impressive in these countries due to strong demand for its products. The company is addressing both the tier-1 and mid-tier markets through its Edge, Truebeam and VitalBeam products. Moreover, the company believes that the Proton system has massive growth potential.
Headquartered in Palo Alto, CA, Varian is a leading provider of radiotherapy, radiosurgery, proton therapy and brachytherapy for the treatment of cancer and other medical conditions. It is also a premier supplier of X-Ray tubes for medical, scientific and industrial applications.
Zacks Rank & Key Picks
Currently, Varian carries a Zacks Rank #3 (Hold).
Better-ranked stocks in the medical sector include GW Pharmaceuticals plc , NuVasive, Inc. and Quidel Corp. (QDEL - Free Report) . Each of these stocks sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>